Aurobindo Pharma Expands Presence in Domestic Formulations Market
Aurobindo Pharma, a leading pharmaceutical company in India, has acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd for a cash consideration of Rs 325 crore. The acquisition, done through its wholly owned subsidiary Auro Pharma Limited, is aimed at strengthening the company’s presence in the domestic formulations market.
Background of the Acquisition
The acquisition takes effect from January 1, 2026, with the cash consideration subject to customary working-capital adjustments. The acquired business comprises 23 established brands across 67 stock-keeping units (SKUs), along with nine pipeline products in the pain management and anti-infective segments.
The acquired business has been operating in the Indian pharmaceutical market since the 1973-74 and has stable revenues over the past three years, indicating its maturity and brand recall in prescription markets. The business is supported by a field force of approximately 470 personnel and a distribution network of over 1,600 stockists across India, which will give Aurobindo immediate scale and market access in these segments.
Strategic Rationale Behind the Acquisition
The acquisition is a strategic move by Aurobindo Pharma to expand its presence in the domestic formulations market. The company has been focusing on strengthening its portfolio in the pain management and anti-infective segments, and the acquisition of Khandelwal Labs’ non-oncology prescription business will help it achieve this goal.
The acquisition will also provide Aurobindo Pharma with access to a large distribution network and a field force of experienced personnel, which will enable the company to increase its market share in the domestic formulations market. The company’s strong product portfolio and distribution network will also help it to capitalize on the growing demand for pharmaceutical products in India.
Impact on the Indian Pharmaceutical Industry
The acquisition of Khandelwal Labs’ non-oncology prescription business by Aurobindo Pharma is expected to have a significant impact on the Indian pharmaceutical industry. The deal is likely to lead to increased competition in the domestic formulations market, which will benefit consumers in the form of lower prices and improved product quality.
The acquisition is also expected to lead to increased investment in research and development, which will help to drive innovation in the Indian pharmaceutical industry. The deal is a testament to the growing importance of the Indian pharmaceutical industry, which has emerged as a major player in the global pharmaceutical market.
Investment Opportunities in the Pharmaceutical Sector
The acquisition of Khandelwal Labs’ non-oncology prescription business by Aurobindo Pharma highlights the investment opportunities available in the pharmaceutical sector. The Indian pharmaceutical industry has been growing rapidly in recent years, driven by factors such as an increasing population, rising income levels, and a growing demand for healthcare services.
Investors looking to invest in the pharmaceutical sector can consider companies such as Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla Limited, which have a strong presence in the domestic formulations market. Investors can also consider investing in pharmaceutical ETFs, which provide a diversified portfolio of pharmaceutical stocks.
Conclusion
In conclusion, the acquisition of Khandelwal Labs’ non-oncology prescription business by Aurobindo Pharma is a strategic move that will help the company to strengthen its presence in the domestic formulations market. The deal is expected to have a significant impact on the Indian pharmaceutical industry, leading to increased competition and investment in research and development.
Investors looking to invest in the pharmaceutical sector should consider the growth prospects of the industry and the investment opportunities available in companies such as Aurobindo Pharma, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla Limited. For more information on pharmaceutical industry news and investment opportunities in the pharmaceutical sector, please visit our website.